Fabentech
- Address
- Immeuble Tony Garnier, 24 Rue Jean Baldassini
Sponsor Overview
Specializations
Antidote and anti-toxin development
Fabentech’s clinical research is centered on antidote and anti-toxin therapeutics, with interest in agents designed to counteract toxic exposures and neutralize harmful biological effects. The sponsor’s current work reflects a focused commitment to toxin neutralization and protective therapy in healthy volunteers.
- Anti-toxin therapeutics
- Toxin neutralization
- Protective biologics
The research landscape is concentrated on evaluating the clinical characteristics of a candidate anti-toxin drug and its relevance to medical countermeasure development.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Tolerability, and Pharmacokinetics of FBT-002 in Healthy Subjects |  France | Not Recruiting |
| Safety and Pharmacokinetics of a Single Intravenous Dose of EuBAT as an Antidote in Healthy Adults: Randomized, Double‑Blind, Placebo‑Controlled Single‑Center Study | France | Not Yet Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 1 site across their trial portfolio.
Therapeutic Focus
- 1.Not possible to specify2 trials230 other sponsors
Partnered Research Centres
1 centre- Address
- 1 Rue Des Essarts, 38610 Gieres
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Fabentech.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.